分拆子公司赴科創板上市,長春高新股價跳漲近4%
昨日晚間,A股市場的分拆大軍迎來了一隻明星股。長春高新(000661.SZ)發佈公告稱,擬將子公司長春百克生物科技股份公司(以下簡稱“百克生物”)分拆至科創板上市。
今日,該公司的股價高開1.84%,此後震盪上升。截至發稿時間,該股的漲幅為3.62%,股價現為675.6元/股,創上市新高,同時也是A股市場第二高價股,已成交6.05億元,最新總市值為1370億元。

(圖片來源:Wind)
資料顯示,長春高新主營業務為生物製藥及中成藥的研發、生產和銷售,輔以房地產開發、物業管理及房產租賃等業務。公司醫藥產品覆蓋創新基因工程製藥、新型疫苗、現代中藥等多個醫藥細分領域,是公司業績的主要來源。
從2019年年報披露的數據來看,基因工程/生物類藥品貢獻了接近79%的營收。

(圖片來源:同花順)
而長春高新子公司百克生物自2004年3月4日成立以來就專注於人用生物疫苗產品的研發、生產與銷售業務,主要產品為水痘疫苗、人用狂犬病疫苗、鼻噴流感疫苗。
截至公告日,上市公司持有百克生物46.15%的股份,而長春高新的實際控制人則是長春新區國資委。
2017年至2019年度,百克生物分別實現營業收入6.91億元、10.19億元、9.84億元,同期的扣非後淨利潤分別為0.88億元、1.88億元、2.13億元。

(圖片來源:長春高新公告)
長春高新表示,此次分拆完成後,公司股權結構不會發生變化且仍擁有對百克生物的控股權。
分拆的目的主要有以下五點:
一是理順業務架構。上市公司與百克生物的採購、生產、銷售等業務模式均存在一定差異。本次分拆後,百克生物可以針對人用生物疫苗的行業特點建立更適應自身的管理方法和組織架構。
二是拓寬融資渠道。本次分拆上市後,百克生物可直接從資本市場獲得股權或債務融資以應對現有業務及未來擴張的資金需求,加速發展並提升經營及財務表現,從而為長春高新和百克生物股東提供更高的投資回報。
三是獲得合理估值。分拆上市有利於資本市場對公司不同業務進行合理估值,從而提高公司整體市值,實現股東利益最大化。
四是完善激勵機制。目前百克生物已經設立了管理層、核心骨幹人員的持股平台。
五是增強競爭能力。分拆後,百克生物可在資本市場靈活融資,拓寬融資渠道,發展多種類、多品種傳染病疫苗產品的研發、生產和銷售業務。
不過,此次的分拆事項尚處於董事會審議通過階段,後續還有很長的路要走。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.